Clinical Report: RA-ILD: Tracking Function and CT
Overview
In a prospective study of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD), pulmonary function and imaging measures remained stable over 24 months despite an 8% mortality rate. The findings challenge conventional expectations of functional decline preceding mortality in ILD.
Background
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a significant cause of morbidity and mortality, often presenting asymptomatically in early stages. Understanding the natural history and progression of RA-ILD is crucial for timely intervention and management. This study provides insights into the stability of pulmonary function and imaging markers over time, which is essential for guiding clinical practice.
Data Highlights
{'6-Minute Walk Distance (m)': {'24 Months': 'Not reported'}}Key Findings
- Stable pulmonary function tests (FVC and FEV1) over 24 months in RA-ILD patients.
- 80% of participants had pulmonary fibrosis, with only 20% classified as usual interstitial pneumonia.
- 12% of patients showed improvement in imaging at 24 months, while 19% worsened.
- 8% mortality rate observed, with no preceding measurable decline in FVC or imaging parameters.
- Circulating biomarkers remained stable and did not differentiate between patients with and without pulmonary fibrosis.
Clinical Implications
The stability of pulmonary function and imaging findings in this cohort suggests that regular monitoring may not always indicate disease progression in RA-ILD. Clinicians should consider a comprehensive approach that includes both functional and imaging assessments for better risk stratification and management of RA-ILD patients.
Conclusion
This study highlights the need for ongoing research into the natural history of RA-ILD and the implications of stable pulmonary function in the context of mortality. Further investigation is warranted to refine prognostic models and treatment strategies.
References
- Kawano-Dourado L, et al., Clinical Rheumatology, 2025 -- RA-ILD: Tracking Function and CT
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease, 2026
- Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial - PMC, 2025
- Int. Journal of Computer Assisted Radiology and Surgery (Springer) — Real-time marker-less needle tracking for CT-guided interventions using multiple RGB cameras
- Journal of Neuro-Oncology — Application of IMRT-Enhanced Radiosurgery for the Management of Multiple or Large Irregular Intracranial Lesions and Evaluation of Infrared Frameless Localization Techniques
- respiTrack: Individualized Real-Time Prediction of Respiratory Tumor Motion Through Magnetic Tracking Techniques
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease
- Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial - PMC
- Rheumatoid arthritis-associated interstitial lung disease (RA- ILD). An Official 2025 ALAT Clinical Practice Guideline - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
